Document text
Principal Investigator: Alexander Gabriel Fiks
Organization: COLUMBIA UNIVERSITY HEALTH SCIENCES
Fiscal Year: 2024
Award: $866,647
Funding agency: National Institute of Allergy and Infectious Diseases
Problem: Influenza and pneumonia is the #8 leading cause of death among children. The influenza vaccine is on the recommended schedule for children and is effective against severe disease. However, families may have different reasons they chose to vaccinate or not vaccinate their child against influenza. Caregivers may want more information about whether their child is at risk for influenza overall or for severe disease and may have doubts regarding vaccine effectiveness and/or vaccine safety. They may also not know when and where they can get the vaccine or what the best time is to be vaccinated for optimal protection, should they decide they want their child to be vaccinated. Pediatricians want families to have the information they would find most helpful to them. Vaccine text messages are widely recommended. Families are busy and often have multiple competing obligations and want information given to them in way that is accessible. Text messaging, as a single-method communication, is a low-cost, scalable, and easy way to provide families with information to help support them to make a vaccine decision they feel is best for their child. If a family does want to be vaccinated, text messages can also help to provide information on when, where and how to get vaccinated. Should they decide not to vaccinate, they can also be well-informed in that decision. We propose a pragmatic implementation study with national scope vital to understanding how best to use influenza text message reminders in a way that is meaningful to parents. AIM 1. To assess the use of influenza vaccine text messages to provide health-related information that parents find informative in deciding whether or not to vaccinate their child against influenza. AIM 2. To assess parental and child characteristics that affect parent engagement with informational influenza vaccine text messages in order to optimize messages for all families AIM 3. To identify contextual factors, facilitators and barriers to implementation and sustainability of health-related text messages for families. Methods: This multi-site trial will include 60,000 parents of 6 month-17-year-old children who are due for the influenza vaccine. Practices will be recruited through a national primary care network. Randomization will occur at the individual level 1:1:1:1 stratified by site, age group, and prior year’s vaccine history: three arms will include different types of educational messages and one arm will be no messages (usual care). Messages will be sent centrally and managed by the research team. Building on results of season 1, we will augment messages based on needs identified and work with families to update messages to best meet their informational needs. We will then conduct a large scale implementation study of the optimized messages in which practices will implement the health-related text messages on their own, should they decide to. Using a mixed-methods approach, we will use the RE-AIM framework in combination with the Consolidated Framework for Implementation Research (CFIR). On a national scale, understanding how to sustainably implement vaccine text messages that meet families’ needs will provide key information to guide future use.
Terms: <0-11 years old><17 year old><17 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Academy><Adolescent><Adolescent Youth><Adoption><American><Application Context><Behavioral><COVID-19><COVID-19 vaccination><COVID-19 vaccine><COVID-19 virus><COVID19 virus><CV-19><Care Givers><Caregivers><Cause of Death><Characteristics><Child><Child Care><Child Youth><Childhood><Children (0-21)><CoV-2><CoV2><Combination Vaccines><Combined Vaccines><Consolidated Framework for Implementation Research><Consolidated Framework for Implementation Science><Consolidated Framework for Implementing Change><Coronavirus Infectious Disease 2019><Disease><Disorder><Dose><Drops><Effectiveness><Family><Flu vaccination><Grippe><Health><Health system><History><Hybrids><Individual><Influenza><Influenza Vaccines><Influenza immunization><Influenza vaccination><Language><Maintenance><Methods><Morbidity><Morbidity - disease rate><Parents><Pediatric Research><Pediatrics><Pneumonia><Policy Maker><Population><Primary Care><Prophylactic vaccination against influenza><Puericulture><RE-AIM><Randomized><Reach, Effectiveness, Adoption, Implementation, and Maintenance><Recommendation><Recording of previous events><Research><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Schedule><Seasons><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Shapes><Site><Testing><Text Messaging><Time><Uncertainty><Vaccination><Vaccines><Wuhan coronavirus><age 17 years><age group><arm><barriers to implementation><care as usual><compare effectiveness><contextual factors><coronavirus disease 2019><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><cost><doubt><effectiveness and implementation trial><effectiveness/implementation hybrid trial><effectiveness/implementation trial><flu immunisation><flu infection><flu vaccine><flu virus infection><flu virus vaccine><global health><hCoV19><hesitant to vaccination><histories><implementation barriers><implementation challenges><implementation strategy><infected with flu><infected with flu virus><infected with influenza><infected with influenza virus><influenza infection><influenza virus infection><influenza virus vaccination><influenza virus vaccine><juvenile><juvenile human><kids><mortality><multi-site trial><multisite trial><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><parent><pediatric><practice setting><practice-based research network><primary care practice><primary outcome><randomisation><randomization><randomly assigned><reach, efficacy, adoption, implementation, and maintenance><recruit><seventeen year old><seventeen years of age><short message service><strategies for implementation><success><texting><treatment as usual><usual care><vaccinate against COVID-19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccination against influenza><vaccination hesitancy><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine against flu><vaccine against influenza><vaccine candidates against SARS-CoV-2><vaccine effectiveness><vaccine for novel coronavirus><vaccine hesitancy><vaccine hesitant><vaccine safety><vaccines preventing COVID><vaccines to prevent COVID><youngster>